Ir para o conteúdo

Michael Marks

@drmichaelmarks.bsky.social did:plc:tcnl3lteuyjseti66zxsbuda

NIHR Research Professor Professor of Medicine at LSHTM. Lead for Integrated Academic Training at LSHTM. Consultant in Infectious Diseases at UCLH. Syphilis & STIs, Neglected Tropical Diseases, Emerging Infectious Diseases, Group A Strep, Pragmatic Trials

No Bluesky desde

Seguidores
6.224
Seguindo
485
Posts
653
Dias nos rankings
0

Resumo

Michael Marks (@drmichaelmarks.bsky.social) é um usuário do Bluesky desde 10 outubro 2024. Tem 6.224 seguidores, segue 485 contas e publicou 653 posts.

Aparições nos rankings

Os melhores dias em que posts desta conta entraram na lista diária do Debya.

Esta conta ainda não apareceu em um ranking diário.

Posts curtidos recentemente

Curtidas públicas da rede Bluesky.

  • Nicole Lieberman, PhD@nicolelieberman.bsky.social

    I’ll be hiring technicians, bioinformaticists, data scientists, and postdocs for a very multidisciplinary team. Graduating soon or looking for a job next summer? Please reach out directly if you’re interested in working with me in Nashville!

    Ver post
  • Nicole Lieberman, PhD@nicolelieberman.bsky.social

    I would be remiss not to share that my brilliant husband Josh (not on Bluesky) will also be joining VUMC as the Medical Director of New Technology and Strategy for Vanderbilt Medical labs, and ID diagnostics service chief. He will be looking for a Leishmania genomics-focused postdoc.

    Ver post
  • Nicole Lieberman, PhD@nicolelieberman.bsky.social

    Ok, part two of my exciting news: I’ll be starting my lab as an Assistant Professor of Pediatrics at Vanderbilt next July, focusing on functional genomics of congenital syphilis.

    Ver post
  • Steven Tong@steventong.bsky.social

    How about ESBLs where pip/taz is better than ceftriaxone? I became more supportive of pip/taz when I realised that for patients with likely GNB sepsis pip/taz had probably 95%+ activity compared to around 85% with ceftriaxone. And that's not because of Pseudomonas.

    Ver post
  • Nicole Lieberman, PhD@nicolelieberman.bsky.social

    Absolutely thrilled to share that my NIAID Director’s New Innovator Award (DP2) has been funded. I’ll be using functional genomics, biochemistry, and immunological techniques to understand the mechanisms and drivers of immune evasion by Treponema pallidum, the bacterium that causes syphilis.

    Ver post

Entre para ver mais

Contas que bloqueia

No Bluesky, bloqueios são registros públicos.